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Green et al., p. 1051; Amendola et al., p. 1067; Jarvik
and Browning, p. 1077
The introduction of next-generation sequencing to the
clinic has spawned a series of questions and challenges
related to standard of care. Recognizing the need to address
these questions and face these challenges head-on, and to
develop best practices for the optimal use and implementa-
tion of genomic testing, the National Human Genome
Research Institute (NHGRI) and the National Cancer Insti-
tute (NCI) initiated the Clinical Sequencing Exploratory
Research (CSER) program. Comprising ten NIH U-awards
and nine related R-awards, the CSER Consortium has
been tasked with exploring the impact of introducing
genomic testing into both preventive and precision medi-
cine. Two papers in this issue highlight recent work from
the Consortium: Green et al. provide an overview of the
CSER Consortium as well as a report on the their progress
to date, and Amendola et al. describe a multi-laboratory
effort to establish best practices for the interpretation of
genomic variants. And in a related paper, Jarvik and
Browning provide guidance for integrating cosegregation
data into variant interpretation guidelines. With the
many resources currently being allocated to precision-
medicine initiatives, it is reassuring to see multi-institu-
tional, cross-disciplinary efforts, such as the CSER Con-
sortium, beginning to bear fruit.Insights into Bacteremia Susceptibility
Rautanen et al., p. 1092
Millions of children each year contract life-threatening
bacterial infections. But why, in the face of identical
exposures, are some people able to fend off disease while
others require urgent medical care? In this issue, Rautanen
and colleagues address this question by performing a
genome-wide association analysis for susceptibility to
bacteremia, or the presence of bacteria in the blood, in
Kenyan children. Kenyans, as well as other sub-Saharan
populations, are at high risk for developing bacteremia, a
condition that can lead to sepsis as well as spread infection
throughout the body. The authors found that a variant in
a lincRNA, AC011288.2, is present at low frequency in
African populations and doubles the risk for bacteremia.
Like most lincRNAs, little is known about AC011288.2,1Deputy Editor, AJHG
http://dx.doi.org/10.1016/j.ajhg.2016.05.017.
The Americbut follow-up analysis by the authors indicates that it is
expressed in neutrophils, lending plausibility to the possi-
bility that this lincRNA plays a role in the immune
response. Future studies will be required to define the
gene(s) regulated by AC011288.2, as well as to explore
in-depth the potential contribution of the risk variant to
clearance of diverse pathogens. Notably, the risk allele is
probably absent in other populations, a finding that serves
as an important reminder of the many insights that can be
gained by including diverse populations in genetic studies.Staving off Hearing Loss with RNAi
Shibata et al., p. 1101
Hearing impairment affects more than 300 million people
worldwide. Although treatment options such as hearing
aids and cochlear implants can improve quality of life,
they are unable to restore normal hearing. Because hearing
loss often results from the expression of dominant gain-
of-function mutations, targeting of the mutant allele,
while maintaining the function of the normal allele, could
potentially mitigate or prevent hearing loss. In this issue,
Shibata et al. demonstrate that a single intracochlear injec-
tion of a microRNA designed to target a single mutant
allele can slow the progression of hearing loss in the Beet-
hoven (Bth) mouse model. This mouse model harbors a
single mutant allele of Tmc1; like their namesake, Bth
mice experience profound hearing loss. An orthologous
mutation in TMC1, which encodes a component of me-
chanotransduction channels present in hair cells of the
inner ear, causes-autosomal dominant hearing loss. Several
technical hurdles will need to be addressed before such
an approach is feasible in humans, but this study suggests
that many cases of hearing loss could be amenable to
miRNA-mediated gene therapy.The Importance of Y
Dumanski et al., p. 1208
Men have a shorter life expectancy than women, and
although behavior certainly contributes to this difference,
genetics are also thought to play a role. Previous work es-
tablished an association betweenmosaic loss of the Y chro-
mosome (LOY) and all-cause mortality. Now, through an
analysis of three independent cohorts, Dumanski et al.
demonstrate that LOY is also a risk factor for Alzheimeran Journal of Human Genetics 98, 1047–1048, June 2, 2016 1047
disease (AD), the most common neurodegenerative disor-
der and an increasingly common cause of death. Notably,
LOY-dependent risk was independent of chronological
age, smoking status, mosaic loss of autosomes, and APOE
genotype. How does LOY play a role in the etiology of
both rare and common disorders that strike late in life?
One idea is that LOY serves as a proxy for biological aging.
It is also possible that LOYarises due to faulty immune sur-
veillance, a condition that is more likely to present with
advancing age and that could contribute to the develop-
ment of numerous pathological conditions. Alternatively,
LOY itself could contribute to disease pathogenesis.
Additional work will be required to provide a clear under-
standing of LOY—its genesis, propagation, and biological
implications.
SMO Mutations in Curry-Jones Syndrome
Twigg et al., p. 1256
Curry-Jones syndrome (CJS), a disorder characterized
by multiple developmental abnormalities, was first recog-1048 The American Journal of Human Genetics 98, 1047–1048, Junenized nearly 30 years ago, but a genetic cause has re-
mained elusive. The rare nature of the disorder, coupled
with the observation of asymmetrical cranial abnormal-
ities, led some clinicians to suspect a mosaic etiology.
Such cases were nearly impossible to solve prior to the
implementation of next-generation sequencing in the
clinic, and even now they require focused analysis of
relevant tissues. In this issue, Twigg et al. identify a single
recurrent somatic mosaic mutation in Smoothened (SMO)
in eight individuals with CJS. This variant, c.1234C>T
(p.Leu412Phe), has been identified as a hotspot mutation
in several tumor types, including those of the skin and
brain. Moreover, there are reports of similar cancers coin-
cident with CJS, and so this genetic discovery has imme-
diate utility for clinical treatment and counseling. SMO
encodes a G-protein-coupled receptor whose function is
crucial for signaling through the hedgehog pathway. In
retrospect, the finding of a mutation that affects the
hedgehog pathway is not entirely unexpected. Indeed,
mutations in other pathway genes can give rise to similar
cranial and limb phenotypes.2, 2016
